Novartis Message Board - Msg: 13074869

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 123.84

+1.0%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Hartmann who wrote (267)	3/6/2000 10:55:00 PM
From: Jack Hartmann	Read Replies (1) of 296

Genentech: Anti-IgE Cut Asthma Exacerbations In Studies March 5, 2000 Dow Jones Newswires SAN DIEGO -- Genentech Inc. (DNA), Novartis AG (Z.NOV) and Tanox Inc. said two Phase III studies show that investigational compound anti-IgE may help improve control of asthma exacerbations and reduce the need for steroids and rescue medication. In a press release, the companies said results from two double-blind, placebo-controlled studies show that treatment with anti-IgE reduced the number of asthma exacerbations. Asthma exacerbations were defined the studies as symptoms requiring a doubling of inhaled steroids or initiation of oral steroids to maintain adequate asthma control. Genentech, Novartis and Tanox are collaborating on Phase III clinical development of anti-IgE. The companies plan to file for regulatory approval in the U.S. and in Europe by the middle of 2000. -Ralph Tasgal; Dow Jones Newswires; 201-938-5400 May can't come soon enough. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next